FGFR4 inhibitors pyrimidine

It relates to compounds of formula (I) wherein: R3 is C1-C6 alkyl, C1-C6 - C1-C6 alkyl, among others; E is -NR 13 C (O) CR14 = CHR15, among others, R13 being hydrogen or methyl, R14 and R15 are hydrogen, methyl, among others; R12 is hydrogen, halo, among others; R1 is phenyl substituted with 2 to 4 halo or C1-C6alkoxy. Specific compounds: N- [2- {6- [3- (2,6-dichloro-3,5-dimethoxy-feniI) -1-methyl-ureido-pyrimidin-4-ylamino} -phenyl) -acrylamide; N- [2- {6- [3- (2,6-dichloro-3,5-dimethoxyphenyl) -1-pyridin-3-ylmethyl-ureido] - pyrimidin-4-ylamino} -phenyl-acrylamide, between others. Also it refers to a pharmaceutical composition and method of treatment. These compounds are inhibitors of FGFR4 being useful in the treatment of hepatocellular carcinoma